RU2006120468A - Система доставки с контролируемым высвобождением для назального применения - Google Patents
Система доставки с контролируемым высвобождением для назального применения Download PDFInfo
- Publication number
- RU2006120468A RU2006120468A RU2006120468/15A RU2006120468A RU2006120468A RU 2006120468 A RU2006120468 A RU 2006120468A RU 2006120468/15 A RU2006120468/15 A RU 2006120468/15A RU 2006120468 A RU2006120468 A RU 2006120468A RU 2006120468 A RU2006120468 A RU 2006120468A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- composition according
- oil
- mixture
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Claims (14)
1. Композиция для назального применения, включающая
a) по меньшей мере один препарат полового гормона;
b) по меньшей мере один липофильный или частично липофильный носитель; и
c) соединение или смесь соединений, обладающих активностью уменьшения поверхностного натяжения, в количестве, эффективном для образования in situ эмульсии при контакте композиции с водой.
2. Композиция по п.1, в которой липофильный носитель включает масло.
3. Композиция по п.2, в которой данное масло представляет собой растительное масло.
4. Композиция по п.3, в которой данное масло представляет собой касторовое масло.
5. Композиция по любому из пп.2-4, в которой содержание масла составляет от 30 до 98 мас.%, предпочтительно от 60 до 98 мас.%, более предпочтительно от 75 до 95 мас.%, еще более предпочтительно от 85 до 95 мас.% и наиболее предпочтительно около 90% массы композиции.
6. Композиция по п.1, в которой компонент (с) включает, по меньшей мере, одно поверхностно-активное вещество, выбранное из группы, состоящей из лецитина, жирнокислотных эфиров многоатомных спиртов, сорбитанов, полиоксиэтиленсорбитанов, полиоксиэтилена, сахарозы, полиглицерина, и/или, по меньшей мере, один увлажнитель, выбранный из группы, состоящей из сорбита, глицерина, полиэтиленгликоля и жирнокислотных эфиров глицерина типа макрогола, либо их смесь.
7. Композиция по п.6, в которой компонент (с) включает олеилмакроголглицерид или смесь олеилмакроголглицеридов.
8. Композиция по п.6 или 7, в которой компонент (с) входит в состав композиции в количестве от 1 до 20 мас.%, предпочтительно от 1 до 10 мас.%, более предпочтительно от 1 до 5 мас.% и наиболее предпочтительно около 4 мас.%.
9. Композиция по п.1, дополнительно включающая средство, регулирующее вязкость.
10. Композиция по п.9, в которой данное средство, регулирующее вязкость, включает загуститель или гелеобразующий агент, выбранный из группы, состоящей из целлюлозы и ее производных, полисахаридов, карбомеров, поливинилового спирта, повидона, коллоидной двуокиси кремния, цетиловых спиртов, стеариновой кислоты, воска, вазелина, триглицеридов и ланолина, либо их смесь.
11. Композиция по п.10, в которой данное средство, повышающее вязкость, представляет собой коллоидную двуокись кремния.
12. Композиция по любому из пп.9-11, в которой средство, регулирующее вязкость, входит в состав композиции в количестве от 0,5 до 10 мас.%, предпочтительно от 0,5 до 5 мас.%, более предпочтительно от 1 до 3 мас.% и наиболее предпочтительно около 3 мас.%.
13. Композиция по п.1, в которой препаратом полового гормона является тестостерон.
14. Композиция по п.1, в которой препарат полового гормона входит в состав композиции в количестве от 0,5 до 6 мас.%, предпочтительно от 2 до 4 мас.%, более предпочтительно от 0,5 до 2 мас.% и наиболее предпочтительно около 2 мас.%.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03025769A EP1530965B1 (en) | 2003-11-11 | 2003-11-11 | Controlled release delivery system of sexual hormones for nasal application |
EP03025769.5 | 2003-11-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006120468A true RU2006120468A (ru) | 2007-12-27 |
RU2331423C2 RU2331423C2 (ru) | 2008-08-20 |
Family
ID=34429314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006120468/15A RU2331423C2 (ru) | 2003-11-11 | 2004-10-27 | Система доставки с контролируемым высвобождением для назального применения |
Country Status (23)
Country | Link |
---|---|
US (6) | US20050100564A1 (ru) |
EP (1) | EP1530965B1 (ru) |
JP (1) | JP4616270B2 (ru) |
KR (1) | KR100861443B1 (ru) |
AR (1) | AR047722A1 (ru) |
AT (1) | ATE319426T1 (ru) |
AU (1) | AU2004286781B2 (ru) |
BR (1) | BRPI0416370B8 (ru) |
CA (1) | CA2541498C (ru) |
DE (1) | DE60303854T2 (ru) |
DK (1) | DK1530965T3 (ru) |
ES (1) | ES2258694T3 (ru) |
HR (1) | HRP20060147B1 (ru) |
MY (1) | MY131483A (ru) |
NO (1) | NO338665B1 (ru) |
PL (1) | PL219338B1 (ru) |
PT (1) | PT1530965E (ru) |
RU (1) | RU2331423C2 (ru) |
SA (1) | SA04250363B1 (ru) |
SI (1) | SI1530965T1 (ru) |
TW (1) | TWI350176B (ru) |
WO (1) | WO2005044273A1 (ru) |
ZA (1) | ZA200603115B (ru) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR199900645T2 (xx) | 1996-10-01 | 1999-07-21 | Fran�Ois Hubert | Bile�ik a��nma par�as�. |
JP4222944B2 (ja) | 2001-12-04 | 2009-02-12 | マゴット アンテルナショナル エス.アー. | 強化された摩耗抵抗性を持つ鋳造部品 |
DE60303854T2 (de) | 2003-11-11 | 2006-08-10 | Mattern, Udo | Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen |
US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
PT1750766E (pt) | 2004-05-11 | 2013-09-30 | Emotional Brain Bv | Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina |
US20060140820A1 (en) | 2004-12-28 | 2006-06-29 | Udo Mattern | Use of a container of an inorganic additive containing plastic material |
EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
EP2068825B1 (en) * | 2006-10-04 | 2011-01-26 | M & P Patent Aktiengesellschaft | Controlled release delivery system for nasal application of neurotransmitters |
US8147980B2 (en) | 2006-11-01 | 2012-04-03 | Aia Engineering, Ltd. | Wear-resistant metal matrix ceramic composite parts and methods of manufacturing thereof |
EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
DE102010023949A1 (de) * | 2010-06-16 | 2011-12-22 | F. Holzer Gmbh | In-situ Lecithin-Mikroemulsionsgel-Formulierung |
GB2482868A (en) | 2010-08-16 | 2012-02-22 | Franciscus Wilhelmus Henricus Maria Merkus | A testosterone liquid spray formulation for oromucosal administration |
US20130040922A1 (en) * | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal 0.45% and 0.48% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US20130040923A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
WO2012156821A1 (en) * | 2011-05-13 | 2012-11-22 | Trimel Pharmaceuticals Corp. | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US20130045958A1 (en) * | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
KR20210135003A (ko) * | 2011-05-15 | 2021-11-11 | 에이세러스 바이오파마 인크. | 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도 |
EA039080B1 (ru) * | 2011-05-16 | 2021-12-01 | Эйсерус Биофарма Инк. | Интраназальные биоадгезивные тестостероновые составы в виде гелей и их применение для лечения мужского гипогонадизма |
EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
JP6262722B2 (ja) | 2012-05-11 | 2018-01-17 | ジェムバックス アンド カエル カンパニー,リミティド | 関節リウマチの予防用または治療用組成物 |
CN115927242A (zh) | 2012-05-11 | 2023-04-07 | 珍白斯凯尔有限公司 | 具有抗炎活性的肽及其在制备抗炎组合物中的应用 |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
CN104822698B (zh) | 2012-07-11 | 2018-08-10 | 珍白斯凯尔有限公司 | 细胞穿透肽以及包含该肽的缀合物和组合物 |
WO2014076569A2 (en) * | 2012-11-14 | 2014-05-22 | Trimel Biopharma Srl | Controlled release topical testosterone formulations and methods |
WO2014083432A2 (en) * | 2012-11-14 | 2014-06-05 | Trimel Biopharma Srl | Female intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
CN105263508B (zh) | 2013-04-19 | 2019-10-25 | 珍白斯凯尔有限公司 | 治疗和预防缺血性损伤的组合物 |
CN105535931A (zh) | 2013-06-07 | 2016-05-04 | 凯尔杰姆维克斯有限公司 | 在癌症免疫疗法中有用的生物标记 |
ES2808076T3 (es) | 2013-06-21 | 2021-02-25 | Gemvax & Kael Co Ltd | Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso |
CN105899224B (zh) | 2013-10-23 | 2019-12-13 | 珍白斯凯尔有限公司 | 用于治疗和预防良性前列腺增生的组合物 |
ES2818921T3 (es) | 2013-11-22 | 2021-04-14 | Gemvax & Kael Co Ltd | Péptido que tiene actividad inhibidora de la angiogénesis y composición que contiene el mismo |
EP3085380B1 (en) | 2013-12-17 | 2020-06-17 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
WO2015156649A1 (ko) | 2014-04-11 | 2015-10-15 | 주식회사 젬백스앤카엘 | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
US10662223B2 (en) | 2014-04-30 | 2020-05-26 | Gemvax & Kael Co., Ltd. | Composition for organ, tissue, or cell transplantation, kit, and transplantation method |
KR20170005819A (ko) | 2014-05-22 | 2017-01-16 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 천연 복합 호르몬 대체 제형 및 요법 |
JP2017523138A (ja) | 2014-07-29 | 2017-08-17 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 経皮クリーム |
CN106922128B (zh) | 2014-08-28 | 2021-04-02 | 得克萨斯州大学系统董事会 | 睾酮制剂及其治疗方法 |
KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
CN107405380B (zh) | 2015-02-27 | 2021-04-20 | 珍白斯凯尔有限公司 | 用于预防听觉损伤的肽及其包含该肽的组合物 |
WO2017003267A1 (ko) | 2015-07-02 | 2017-01-05 | 주식회사 젬백스앤카엘 | 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
BR102015020878B1 (pt) * | 2015-08-28 | 2019-08-27 | F B M Ind Farmaceutica Ltda | formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona. |
CA3016542A1 (en) * | 2016-03-02 | 2017-09-08 | Board Of Regents, The University Of Texas System | Formulations of testosterone and methods of treatment therewith |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
JP7114481B2 (ja) | 2016-04-07 | 2022-08-08 | ジェムバックス アンド カエル カンパニー,リミティド | テロメラーゼ活性の増加及びテロメアの延長の効能を有するペプチド、及びこれを含む組成物 |
EA201892595A1 (ru) | 2016-06-03 | 2019-06-28 | М Эт П Фарма Аг | Назальные фармацевтические композиции с пористым наполнителем |
RU2019123307A (ru) | 2017-01-20 | 2021-02-20 | М Эт П Фарма Аг | Фармацевтические композиции для назального введения для снижения рисков воздействия загрязнителей воздуха |
ES2807798T3 (es) | 2017-02-02 | 2021-02-24 | Otolanum Ag | Composición intranasal que comprende betahistina |
EP3718550A4 (en) * | 2017-11-27 | 2021-08-25 | ASKA Pharmaceutical Co., Ltd. | POWDER PREPARATION FOR NASAL ADMINISTRATION |
CN111902188A (zh) | 2018-01-11 | 2020-11-06 | 马特恩制药股份公司 | 脱髓鞘疾病的治疗 |
EP3773497B1 (en) | 2018-04-09 | 2023-10-18 | Elgan Pharma Ltd. | Oxytocin compositions and methods of use |
US20220062165A1 (en) | 2018-04-17 | 2022-03-03 | M et P Pharma AG | Compositions and methods for intranasal delivery of pregnenolone |
AU2019365255A1 (en) * | 2018-10-26 | 2021-06-03 | Viramal Limited | Mucoadhesive gel composition |
CA3123301A1 (en) * | 2018-12-14 | 2020-06-18 | Acerus Biopharma Inc. | Nasal pharmaceutical testosterone ester gel compositions for nasal administration and method |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE943792C (de) * | 1949-02-18 | 1956-06-01 | Organon Nv | Verfahren zur Herstellung von injizierbaren Hormonpraeparaten |
GB1032874A (en) | 1964-02-13 | 1966-06-15 | Du Pont | Stabilized polyoxymethylenes |
NL7506407A (nl) * | 1975-05-30 | 1976-12-02 | Akzo Nv | Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat. |
NL7510104A (nl) * | 1975-08-27 | 1977-03-01 | Akzo Nv | Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat. |
DE2548413A1 (de) * | 1975-10-27 | 1977-04-28 | Schering Ag | Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion |
US4315925A (en) * | 1980-05-30 | 1982-02-16 | University Of Kentucky Research Foundation | Method of administering natural female sex hormones |
US4581225A (en) * | 1984-04-25 | 1986-04-08 | Eli Lilly And Company | Sustained release intranasal formulation and method of use thereof |
US4752425A (en) * | 1986-09-18 | 1988-06-21 | Liposome Technology, Inc. | High-encapsulation liposome processing method |
US5049387A (en) * | 1987-03-09 | 1991-09-17 | Alza Corporation | Inducing skin tolerance to a sensitizing drug |
US5690954A (en) * | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
JP2543708B2 (ja) * | 1987-07-13 | 1996-10-16 | 旭化成工業株式会社 | 難溶性薬物を封入したエマルジョン製剤の製造方法 |
NL8801670A (nl) * | 1988-07-01 | 1990-02-01 | Walter Adrianus Josephus Johan | Farmaceutisch preparaat. |
GB2237510B (en) | 1989-11-04 | 1993-09-15 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
US5397771A (en) * | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
US5221698A (en) | 1991-06-27 | 1993-06-22 | The Regents Of The University Of Michigan | Bioactive composition |
US5756071A (en) * | 1992-06-03 | 1998-05-26 | Arrowdean Limited | Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier |
SE9301171D0 (sv) * | 1993-04-07 | 1993-04-07 | Ab Astra | Pharmaceutical composition containing lipophilic drugs |
ATE201980T1 (de) | 1994-02-04 | 2001-06-15 | Scotia Lipidteknik Ab | Präparate mit lipophilen trägerstoffen |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5635203A (en) | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
GB9608719D0 (en) | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
GB9707934D0 (en) | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
US5897894A (en) * | 1997-12-29 | 1999-04-27 | General Mills, Inc. | Microwave popcorn with coarse salt crystals and method of preparation |
GB9823246D0 (en) * | 1998-10-24 | 1998-12-16 | Danbiosyst Uk | A nasal drug delivery composition |
GB9828861D0 (en) | 1998-12-31 | 1999-02-17 | Danbiosyst Uk | Compositions |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
NZ514290A (en) * | 1999-04-01 | 2003-08-29 | Akzo Nobel Nv | Formulation comprising testosterone undecanoate and castor oil |
US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
CO5180583A1 (es) | 1999-06-11 | 2002-07-30 | Watson Pharmaceuticals Inc | Administracion de esteroides androgenicos no orales a las mujeres |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
CA2383233C (en) * | 1999-09-21 | 2010-06-08 | Rtp Pharma Inc. | Surface modified particulate compositions of biologically active substances |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
AU1261501A (en) | 1999-12-06 | 2001-06-18 | Stanley L. Gore | Compositions and methods for intranasal delivery of active agents to the brain |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
US20040092494A9 (en) | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
US20020072509A1 (en) | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
US6730330B2 (en) * | 2001-02-14 | 2004-05-04 | Gw Pharma Limited | Pharmaceutical formulations |
WO2002069906A2 (en) * | 2001-03-06 | 2002-09-12 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
US6833478B2 (en) | 2001-07-13 | 2004-12-21 | Sri International | N,N-dinitramide salts as solubilizing agents for biologically active agents |
JP2005523262A (ja) * | 2002-02-01 | 2005-08-04 | ファイザー・プロダクツ・インク | 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物 |
IL163981A0 (en) | 2002-03-15 | 2005-12-18 | Unimed Pharmaceuticals Inc | Androgen pharmaceutical composition and method fortreating depression |
US6855332B2 (en) * | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
US7029657B2 (en) | 2002-08-02 | 2006-04-18 | Balance Pharmaceuticals, Inc. | Nasal spray steroid formulation and method |
US6958142B2 (en) | 2002-08-02 | 2005-10-25 | Balance Pharmaceuticals, Inc. | Nasal spray formulation and method |
US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
DE60303854T2 (de) | 2003-11-11 | 2006-08-10 | Mattern, Udo | Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen |
WO2005065185A2 (en) | 2003-12-24 | 2005-07-21 | Collegium Pharmaceuticals, Inc. | Temperature-stable formulations, and methods of development thereof |
US20060140820A1 (en) | 2004-12-28 | 2006-06-29 | Udo Mattern | Use of a container of an inorganic additive containing plastic material |
EP2068825B1 (en) | 2006-10-04 | 2011-01-26 | M & P Patent Aktiengesellschaft | Controlled release delivery system for nasal application of neurotransmitters |
-
2003
- 2003-11-11 DE DE60303854T patent/DE60303854T2/de not_active Expired - Lifetime
- 2003-11-11 EP EP03025769A patent/EP1530965B1/en not_active Expired - Lifetime
- 2003-11-11 ES ES03025769T patent/ES2258694T3/es not_active Expired - Lifetime
- 2003-11-11 DK DK03025769T patent/DK1530965T3/da active
- 2003-11-11 AT AT03025769T patent/ATE319426T1/de active
- 2003-11-11 SI SI200330194T patent/SI1530965T1/sl unknown
- 2003-11-11 PT PT03025769T patent/PT1530965E/pt unknown
-
2004
- 2004-02-04 US US10/772,964 patent/US20050100564A1/en not_active Abandoned
- 2004-09-23 MY MYPI20043889A patent/MY131483A/en unknown
- 2004-10-04 TW TW093129982A patent/TWI350176B/zh not_active IP Right Cessation
- 2004-10-05 AR ARP040103611A patent/AR047722A1/es not_active Application Discontinuation
- 2004-10-27 ZA ZA200603115A patent/ZA200603115B/en unknown
- 2004-10-27 CA CA002541498A patent/CA2541498C/en active Active
- 2004-10-27 PL PL379867A patent/PL219338B1/pl unknown
- 2004-10-27 JP JP2006538697A patent/JP4616270B2/ja not_active Expired - Fee Related
- 2004-10-27 WO PCT/EP2004/012122 patent/WO2005044273A1/en not_active Application Discontinuation
- 2004-10-27 RU RU2006120468/15A patent/RU2331423C2/ru active
- 2004-10-27 BR BRPI0416370A patent/BRPI0416370B8/pt not_active IP Right Cessation
- 2004-10-27 AU AU2004286781A patent/AU2004286781B2/en not_active Ceased
- 2004-10-27 KR KR1020067009182A patent/KR100861443B1/ko active IP Right Grant
- 2004-11-02 SA SA04250363A patent/SA04250363B1/ar unknown
-
2006
- 2006-04-18 HR HRP20060147AA patent/HRP20060147B1/hr not_active IP Right Cessation
- 2006-06-07 NO NO20062619A patent/NO338665B1/no not_active IP Right Cessation
- 2006-11-15 US US11/560,187 patent/US20070149454A1/en not_active Abandoned
-
2010
- 2010-06-08 US US12/796,165 patent/US20100311707A1/en not_active Abandoned
-
2011
- 2011-07-29 US US13/194,853 patent/US8784882B2/en not_active Expired - Lifetime
- 2011-07-30 US US13/194,928 patent/US8574622B2/en not_active Expired - Lifetime
- 2011-12-10 US US13/316,494 patent/US8877230B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006120468A (ru) | Система доставки с контролируемым высвобождением для назального применения | |
RU2009116609A (ru) | Система доставки с контролируемым высвобождением для назального применения нейротрансмиттеров | |
CA2037487C (en) | Nitroglycerin pump spray | |
RU2381794C2 (ru) | Содержащая амброксол композиция для местного применения | |
US4963555A (en) | Formulations of heterocyclic compounds | |
ATE207346T1 (de) | Orale pharmazeutische zusammensetzungen mit sexualhormonen | |
DE69901951T2 (de) | Verwendung gelierbarer pharmazeutischer zusammensetzungen in der parodontologie | |
CA1172169A (en) | Formulations of heterocyclic compounds | |
US4783332A (en) | Novel skin tanning composition | |
KR100383252B1 (ko) | 부프레놀핀을함유하는경피투여조성물및이를포함하는패취 | |
KR100352088B1 (ko) | 미녹시딜 함유 외용 에멀젼 조성물 | |
JPH0380775B2 (ru) | ||
CA1169770A (en) | Antimycotic agent, in the form of sticks, with a high release of active compound | |
DE60205633D1 (de) | Orale pharmazeutische zusammensetzung mit einem wirkstoff, der bei seiner ersten darmpassage starken wirkungen ausgesetzt werden kann | |
US20140066481A1 (en) | Water-Free Pharmaceutical Compositions Suitable for Local Anaesthetics | |
EP0651993B1 (en) | Percutaneously administrable base composition and drug composition prepared therefrom | |
HRP20020154B1 (en) | Pharmaceutical compositions for oral and topical administration | |
EP0175609B1 (fr) | Composition anesthésique percutanée pour usage topique et procédé d'application | |
CA2470230A1 (en) | Pharmaceutical formulation comprising cyclosporin and use thereof | |
KR20080034916A (ko) | 에피나스틴을 포함하는 경피 흡수 안과 제제 | |
FR2609394A1 (fr) | Solution aqueuse contenant un acide quinolone carboxylique | |
JP2001064206A (ja) | 経皮吸収促進組成物 | |
WO2013182688A1 (en) | A topical gel composition comprising an ingenol derivative and a solvent mixture | |
JP2012526738A5 (ru) | ||
KR20000022734A (ko) | Sedds로 제제화한 발기부전치료용 주입액제 |